Literature DB >> 8243609

Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562.

P Tosi1, G Visani, E Ottaviani, B Gamberi, A Cenacchi, S Tura.   

Abstract

We have previously reported that the antineoplastic activity of 3'-azido 3' deoxythymidine (AZT) can be increased by drugs that inhibit "de novo" thymidylate synthesis, such as 5-fluorouracil, methotrexate and hydroxyurea. In the present study we tested the combinations AZT+alpha interferon (IFN) and AZT+gamma IFN on in vitro growth of the human acute-phase chronic myeloid leukemia (CML) cell line K562. After 72 hours incubation, not only AZT+alpha-IFN but also AZT+gamma-IFN were synergistic in inhibiting K562 growth, as demonstrated by isobologram analysis of the data. This enhanced cytotoxicity was confirmed by the evaluation of [3H]AZT incorporation into cellular DNA, that was increased by 50% and 222% in the presence of alpha- and gamma-IFN, respectively. The addition of 50 mumol/l thymidine to the culture medium was able to reduce the cytotoxicity of the drug combinations to the degree observed with each compound alone; furthermore, the increased incorporation of AZT into DNA was completely reversed. These data indicate the existence of a biochemical interaction between AZT and IFNs that results in an increased cytotoxic effect. While the combination AZT+alpha-IFN is currently being tested in HIV-related malignancies, AZT+gamma-IFN is new and deserves further study in human CML acute and chronic phase models, in view of possible clinical applications.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8243609     DOI: 10.1111/j.1600-0609.1993.tb00632.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.

Authors:  J Clark; W Sikov; F Cummings; M Browne; W Akerley; H Wanebo; A Weitberg; T Kennedy; B Cole; J Bigley; J Beitz; J Darnowski
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 2.  Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?

Authors:  Rihab Nasr; Hiba El Hajj; Youmna Kfoury; Hugues de Thé; Olivier Hermine; Ali Bazarbachi
Journal:  Viruses       Date:  2011-06-14       Impact factor: 5.048

Review 3.  Current status of therapeutic approaches to adult T-cell leukemia.

Authors:  Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.319

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.